Innovative Immunotherapies Candel Therapeutics specializes in developing off-the-shelf multimodal biological immunotherapies for cancer treatment, using novel genetically modified viruses, which positions the company at the forefront of the immuno-oncology market and presents opportunities to collaborate with healthcare providers seeking cutting-edge cancer therapies.

Expanding Clinical Pipeline With multiple product candidates in phase 2 and phase 3 clinical trials across various cancer types, Candel offers multiple engagement points for hospitals and clinics involved in oncological research and treatment, opening avenues for pilot programs, clinical partnerships, and early adoption sales.

Strategic Partnerships & Funding Recent collaborations with Batavia Biosciences and RTW Investments, along with substantial growth capital from Trinity Capital, demonstrate strong external support and validation of their pipeline, which can facilitate co-development opportunities and joint ventures in viral immunotherapy distribution.

Recent Product Launches The company’s recent launch of aglatimagene besadenovec in localized prostate cancer and its presentations at major scientific meetings suggest an active strategy to penetrate specialized oncology markets, creating opportunities to target academic institutions and specialty healthcare providers for early adoption.

Technological Edge Utilizing advanced viral discovery platforms and establishing scalable manufacturing processes signals a robust technological foundation, enabling B2B partnerships with biotech firms and contract manufacturing organizations seeking innovative cancer immunotherapeutics.